Guy Brusselle
Guy Brusselle is an expert in Pulmonology at Ghent University Hospital (Belgium). As of October 2026, ScienceLeadR ranks Guy Brusselle in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Guy Brusselle has authored 723 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 2 of them ongoing. SLR score: 2,738 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Immunology - Critical Care - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1994 - 2026
Number : 723
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Tozorakimab to Prevent COPD Exacerbations. PMID 42708515 — smokers, maintenance, pulmonary disease, chronic obstructive, therapeutics, interleukin-33 | N Engl J Med Top journal | 2026 | 4 |
| Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study. PMID 42936732 — registries, comorbidity, documentation, physicians, prevalence, multimorbidity, asthma, steroids, education, gastroesophageal reflux | J Asthma Allergy | 2026 | 0 |
| A Proposed Consensus Definition of Severe COPD: a modified Delphi Study. PMID 42885566 — research design, quality of life, signs and symptoms, pulmonary disease, chronic obstructive, work, risk factors, therapeutics | Ann Am Thorac Soc | 2026 | 0 |
| 2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes. PMID 42847657 — respiratory tract diseases, adrenal cortex hormones, critical care, adolescent, diagnosis, morbidity, therapeutics, asthma, child | Am J Respir Crit Care Med | 2026 | 0 |
| Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies. PMID 42624803 — lung, blood, cohort studies, eosinophils, therapeutics, asthma, prospective studies | Lancet Respir Med Top journal | 2026 | 1 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma 2024-512113-41-00 — maintenance, therapeutics, asthma | Phase 3 | Active not recruiting | 2024 |
| A Study to Learn About the Study Medicine Called PF 07275315 in People With Moderate to Severe Asthma 2024-517866-40-00 — safety, asthma | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map